Inhibiting the Precipitation of Poorly Water-Soluble Drugs from Labrasol Formulations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inhibiting the Precipitation of Poorly Water-Soluble Drugs from Labrasol Formulations
The study results suggested that Pluronic F127 might be a potent inhibitor of drug precipitation for Labrasol formulations.


Pharmaceutical Technology
Volume 35, Issue 6, pp. 50-54

References

1. R. Lipper, Modern Drug Discov. 2 (1), 255–260 (1999).

2. C.A. Lipinski, American Pharm. Rev. (Fall), 582–585 (2002).

3. C.A. Lipinski, J. Pharmacol. Toxicol. Methods 44 (1), 235–249 (2001).

4. R.A. Prentis, Y. Lis, and S.R. Walker, Br. J. Clin. Pharmacol. 25 (3), 387–396 (1988).

5. S.H. Yalkowsky, Solubility and Solubilization in Aqueous Media, S.H. Yalkowsky, Ed. (Oxford Univeristy Press, New York, 2000).

6. R.G. Strickley, Pharm. Res. 21 (2), 201–230 (2004).

7. P.C. Sheen et al., Int. J. Pharm. 118 (2), 221–227 (1995).

8. S. Fernandez et al., Pharm. Res. 26 (8), 1901–1910 (2009).

9. W.G. Dai, Int. J. Pharm. 393 (1–2), 1–16 (2010).

10. W.G. Dai et al., J. Pharm. Sci. 96 (11), 2957–2969 (2007).

11. B.A. Hoener and L.Z. Benet, "Factors Influencing Drug Absorption and Drug Availability," in Drugs and the Pharmaceutical Sciences, G.S. Banker and C. Rhodes, Eds. (Informa Healthcare, New York, 4th ed., 2002), pp. 93–117.

12. S. Barakat Nahla, J. Pharm. Pharmacol. 62 (2), 173–180 (2010).

13. T.R. Kommuru et al., Int. J. Pharm. 212 (2), 233–246 (2001).

14. H.J. Kim et al, Drug Dev. Ind. Pharm. 26 (5), 523–529 (2000).

15. G. Venkatesh et al., Drug Dev. Ind. Pharm. 36 (6), 735–745 (2010).

16. W.G. Dai et al., Int. J. Pharm. 336 (1), 1–11 (2007).

17. W.G. Dai et al., Adv. Drug Deliv. Rev. 60 (6), 657–672 (2008).

18. A.R. Das et al., J. Surf. Sci. Technol. 14 (1–4), 41–47 (1998).

19. M.G. Neumann, C.C. Schmitt, and E.T. Iamazaki, Carbohydr. Res. 338 (10), 1109–1113 (2003).

20. T. Yoshimura, A. Ohno, and K. Esumi, J. Colloid Interface Sci. 272 (1), 191–196 (2004).

21. V.A.d.O. Tiera, M.J. Tiera, and M.G. Neumann, J. Dispers. Sci. Technol. 22 (2 & 3), 177–184 (2001).

22. M.S. Bakshi et al., J. Colloid Interface Sci. 286 (1), 369–377 (2005).

23. P.A. Bhat, G.M. Rather, and A.A. Dar, J. Phys. Chem. B 113 (4), 997–1006 (2009).

24. L.S.C. Wan and P.F.S. Lee, Can. J. Pharm. Sci. 10 (3), 69–73 (1975).

25. M.S. Bakshi and K. Singh, J. Colloid Interface Sci. 287 (1), 288–297 (2005).

26. M.S. Bakshi et al., Colloids Surf. A Physicochem. Eng. Asp. 278 (1–3), 129–139 (2006).

27. W.G. Dai et al., Int. J. Pharm. 355 (1–2), 31–37 (2008).

Citation: When referring to this article, please cite it as "W.G. Dai, L.C. Dong, and A.A. Creasey, "Inhibiting the Precipitation of Poorly Water Soluble Drugs from Labrasol Formulations," Pharmaceutical Technology 35 (6) 50-54(2011)."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here